(Updates with share price movement in the headline, and first and second paragraphs.) Celldex Therapeutics' (CLDX) shares declined Friday morning, a day...
Celldex Therapeutics (CLDX) has an average rating of buy and price targets ranging from $59 to $68, according to analysts polled by Capital IQ. (MT...
Health care stocks were mixed premarket Friday. The Health Care SPDR (XLV) was 0.28% lower, and the iShares NASDAQ Biotechnology Index (IBB) was recently...
Celldex Therapeutics (CLDX) said Thursday that its candidate therapy for moderate to severe chronic spontaneous urticaria (CSU), barzolvolimab, showed...
| Address | Perryville III Building Hampton, New Jersey 08827 |
| Phone | +1.908.200.7500 |
| Number of Employees | 137 |
| Recent SEC Filing | 06/23/2022 8-K |
| President, Chief Executive Officer & Director | Anthony S. Marucci |
| CFO, Secretary, Treasurer & Senior Vice President | Sam Martin |
| Chief Scientific Officer & Executive VP | Tibor Keler |
| Chief Medical Officer & Senior Vice President | Diane C. Young |
| Price Open | $23.56 |
| Previous Close | $26.96 |
| 52 Week Range | $19.85 - 57.20 |
| Market Capitalization | $1.1 B |
| Shares Outstanding | 46.8 M |
| Sector | Health Technology |
| Industry | Medical Specialties | Next Earnings Announcement | 08/04/2022 |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$1.69 |
| Beta vs. S&P 500 | N/A |
| Revenue | $9.5 M |
| Net Profit Margin | -1,860.01% |
| Return on Equity | -21.45% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
